{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:42:49Z","timestamp":1792510969811,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Taxane-induced peripheral neuropathy (TIPN) affects quality of life and ability to complete cancer treatment and has limited effective interventions for prevention and treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To develop and validate a TIPN risk prediction model.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n SWOG S1714 was a prospective observational cohort study conducted at sites in the National Cancer Institute National Community Oncology Research Program between March 1, 2019, and November 15, 2021, with 3 years of follow-up. The study included evaluable participants 18 years or older with stage I to III lung, breast, or ovarian, fallopian tube, or primary peritoneal cancer who were starting taxane-based treatment. Statistical analysis was conducted from December 2023 to June 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Taxane-based regimens including paclitaxel or docetaxel.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n \n The primary end point was occurrence of TIPN by 24 weeks. TIPN was assessed using the patient-reported European Organization of Research and Treatment of Cancer Quality of Life Questionnaire\u2013Chemotherapy-Induced Peripheral Neuropathy 20-item scale (CIPN-20) at baseline and weeks 4, 8, 12, and 24. Occurrence of TIPN was defined as an increase of 8 points or more over baseline in the CIPN-20 sensory subscale score. With a 60% random sample of evaluable participants, best-subset selection using logistic regression and\n k<\/jats:italic>\n -fold cross-validation identified a best model based on demographic factors, baseline comorbid conditions, and treatment factors. Adverse risk factors were summed, generating a score, split at the median and tested in the remaining 40% of evaluable participants. The target difference was 12% between high-risk vs low-risk groups.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 1336 participants enrolled in S1714. Of 1278 evaluable participants (median age, 55.0 years [range, 23.0-84.0 years]; 1264 women [98.9%]; 1164 with breast cancer [91.1%]), 804 (62.9%) experienced TIPN by week 24. Using the training set of 768 participants, a risk prediction model for TIPN was developed that included 5 adverse risk factors: receipt of paclitaxel; stage II or III disease; planned taxane duration of more than 12 weeks; diabetes, autoimmune disease, moderate kidney disease, or a neurologic condition; and self-identified race and ethnicity (Black, Hispanic, Native American, Pacific Islander, multiple races, or unknown race or ethnicity). In the test set of 510 participants, TIPN was more common in high-risk (235 of 345 [68.1%]) vs low-risk (84 of 165 [50.9%]) groups (absolute difference, 17.2%), exceeding the 12% target.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of participants with early-stage cancer receiving a taxane regimen, a set of baseline risk factors stratified TIPN risk. A risk prediction model may guide treatment decision-making, symptom monitoring, and enrollment in interventional trials for TIPN prevention and treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.4901","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:30:56Z","timestamp":1775835056000},"page":"e264901","source":"Crossref","is-referenced-by-count":3,"title":["Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer"],"prefix":"10.1001","volume":"9","author":[{"given":"Meghna S.","family":"Trivedi","sequence":"first","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Unger","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Seattle, Washington"},{"name":"Fred Hutch Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Darke","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Seattle, Washington"},{"name":"Fred Hutch Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Brannagan","sequence":"additional","affiliation":[{"name":"Peripheral Neuropathy Center, Columbia University Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Reyes","sequence":"additional","affiliation":[{"name":"Nancy N. and J. C. Lewis Cancer and Research Pavilion at St Joseph\u2019s\/Candler Oncology Clinical Research, Savannah, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology\/Oncology, Indiana University School of Medicine, Indianapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"William J.","family":"Irvin","sequence":"additional","affiliation":[{"name":"Bon Secours Saint Francis Medical Center Cancer Institute\/Southeast Clinical Oncology Research (SCOR), Midlothian, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Hathaway","sequence":"additional","affiliation":[{"name":"University Cancer & Blood LLC, Athens, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Vander Woude","sequence":"additional","affiliation":[{"name":"The Cancer & Hematology Centers, Grand Rapids, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay K.","family":"Gudena","sequence":"additional","affiliation":[{"name":"Cone Health Cancer Center, Greensboro, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Cabrera-Galeana","sequence":"additional","affiliation":[{"name":"Division of Oncology and Hematology, Instituto Nacional de Cancerolog\u00eda, M\u00e9xico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Orsted","sequence":"additional","affiliation":[{"name":"HealthPartners Cancer Center at Regions Hospital, St Paul, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"SWOG Cancer Research Network Statistics and Data Management Center, Seattle, Washington"},{"name":"Fred Hutch Cancer Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Fisch","sequence":"additional","affiliation":[{"name":"Department of General Oncology, MD Anderson Cancer Center, Houston, Texas"},{"name":"Specialty Care Solutions, Carelon Medical Benefits Management, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Hershman","sequence":"additional","affiliation":[{"name":"Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"5","key":"zoi260179r1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/oxfordjournals.annonc.a059220","article-title":"Paclitaxel-induced neuropathy.","volume":"6","author":"Postma","year":"1995","journal-title":"Ann Oncol"},{"key":"zoi260179r2","author":"Rowinsky","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"10","key":"zoi260179r3","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1007\/s00520-019-04987-8","article-title":"Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.","volume":"27","author":"Chan","year":"2019","journal-title":"Support Care Cancer"},{"issue":"12","key":"zoi260179r4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"28","key":"zoi260179r5","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO guideline update.","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi260179r6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.ctrv.2014.04.004","article-title":"Chemotherapy-induced neuropathy: a comprehensive survey.","volume":"40","author":"Miltenburg","year":"2014","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"zoi260179r7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/BF01213547","article-title":"Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of life.","volume":"122","author":"Markman","year":"1996","journal-title":"J Cancer Res Clin Oncol"},{"issue":"23","key":"zoi260179r8","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.2016.71.3552","article-title":"Falls, functioning, and disability among women with persistent symptoms of chemotherapy-induced peripheral neuropathy.","volume":"35","author":"Winters-Stone","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260179r9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00059","article-title":"Impact of genetic ancestry on outcomes in ECOG-ACRIN-E5103.","volume":"2017","author":"Schneider","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"25","key":"zoi260179r10","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2015.66.2346","article-title":"Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials.","volume":"34","author":"Hershman","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260179r11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw206","article-title":"BMI, lifestyle factors and taxane-induced neuropathy in breast cancer patients: the Pathways Study.","volume":"109","author":"Greenlee","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"24","key":"zoi260179r12","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1200\/JCO.24.00526","article-title":"ECOG-ACRIN EAZ171: prospective validation trial of germline predictors of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer.","volume":"42","author":"Schneider","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260179r13","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3727\/096504012X13522227232192","article-title":"Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non\u2013small cell lung cancer.","volume":"20","author":"Kawakami","year":"2012","journal-title":"Oncol Res"},{"issue":"1","key":"zoi260179r14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/jns.12616","article-title":"Incidence and risk factors for developing chemotherapy-induced neuropathic pain in 500 cancer patients: a file-based observational study.","volume":"29","author":"Argyriou","year":"2024","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"zoi260179r15","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/cncr.22921","article-title":"Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.","volume":"110","author":"Badros","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"zoi260179r16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur J Haematol"},{"issue":"2","key":"zoi260179r17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s10549-021-06304-6","article-title":"Longitudinal study of inflammatory, behavioral, clinical, and psychosocial risk factors for chemotherapy-induced peripheral neuropathy.","volume":"189","author":"Kleckner","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"zoi260179r18","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1312","article-title":"Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.","volume":"9","author":"Molassiotis","year":"2019","journal-title":"Brain Behav"},{"issue":"11","key":"zoi260179r19","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.6004\/jnccn.2023.7062","article-title":"Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in SWOG S0221.","volume":"21","author":"Chen","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi260179r20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.critrevonc.2017.09.009","article-title":"The molecular genetics of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.","volume":"120","author":"Cliff","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"11","key":"zoi260179r21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.39788","article-title":"Association of taxane type with patient-reported chemotherapy-induced peripheral neuropathy among patients with breast cancer.","volume":"5","author":"Mo","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"16","key":"zoi260179r22","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","article-title":"Weekly paclitaxel in the adjuvant treatment of breast cancer.","volume":"358","author":"Sparano","year":"2008","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi260179r23","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"8","key":"zoi260179r24","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ejca.2005.02.012","article-title":"The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.","volume":"41","author":"Postma","year":"2005","journal-title":"Eur J Cancer"},{"issue":"10","key":"zoi260179r25","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1007\/s11136-013-0379-8","article-title":"Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.","volume":"22","author":"Lavoie Smith","year":"2013","journal-title":"Qual Life Res"},{"issue":"21","key":"zoi260179r26","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","article-title":"Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry.","volume":"31","author":"Mols","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi260179r27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mds329","article-title":"The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.","volume":"24","author":"Cavaletti","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi260179r28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/00401706.1974.10489231","article-title":"Regressions by leaps and bounds.","volume":"16","author":"Furnival","year":"1974","journal-title":"Technometrics"},{"issue":"1","key":"zoi260179r30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve.","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"zoi260179r31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","article-title":"Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature.","volume":"6","author":"Argyriou","year":"2014","journal-title":"Cancer Manag Res"},{"issue":"10","key":"zoi260179r32","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdw290","article-title":"Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non\u2013small-cell lung cancer (NSCLC).","volume":"27","author":"Joerger","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"zoi260179r33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s10147-011-0352-x","article-title":"Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer.","volume":"18","author":"Tanabe","year":"2013","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"zoi260179r34","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx162","article-title":"Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG Oncology\/NSABP B-30.","volume":"110","author":"Bandos","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi260179r35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41416-021-01429-3","article-title":"Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort.","volume":"125","author":"Engvall","year":"2021","journal-title":"Br J Cancer"},{"key":"zoi260179r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104739","article-title":"Review of the contribution of clinical and genetic factors to the racial disparity in taxane-induced peripheral neuropathy.","volume":"211","author":"Nguyen-Hoang","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"zoi260179r37","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1038\/s41591-022-01781-8","article-title":"Patient reported outcome assessment must be inclusive and equitable.","volume":"28","author":"Calvert","year":"2022","journal-title":"Nat Med"},{"key":"zoi260179r38","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/jns.12335","article-title":"Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment.","volume":"24","author":"Staff","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"zoi260179r39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrclinonc.2015.222","article-title":"Patient-reported outcomes in the evaluation of toxicity of anticancer treatments.","volume":"13","author":"Di Maio","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"zoi260179r40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdt409","article-title":"Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.","volume":"25","author":"Alberti","year":"2014","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi260179r41","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.24139","article-title":"Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy.","volume":"7","author":"Li","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"18","key":"zoi260179r42","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2013.54.0914","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.","volume":"32","author":"Hershman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi260179r43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1200\/JCO.2010.31.5911","article-title":"Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.","volume":"29","author":"Grothey","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi260179r44","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1186\/s12885-021-08240-6","article-title":"Compression therapy using surgical gloves does not prevent paclitaxel-induced peripheral neuropathy: results from a double-blind phase 2 trial.","volume":"21","author":"Kotani","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"zoi260179r45","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jamaoncol.2025.0001","article-title":"Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial.","volume":"11","author":"Michel","year":"2025","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi260179r46","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1007\/s00520-019-05254-6","article-title":"Reporting of paclitaxel-induced peripheral neuropathy symptoms to clinicians among women with breast cancer: a qualitative study.","volume":"28","author":"Salgado","year":"2020","journal-title":"Support Care Cancer"},{"key":"zoi260179r29","unstructured":"Kohavi? R. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence; August 20-25, 1995; Montreal, Quebec, Canada; 1995:1137-1145. Accessed January 15, 2024. https:\/\/www.ijcai.org\/Proceedings\/95-2\/Papers\/016.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2847639\/trivedi_2026_oi_260179_1775233649.73998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:30:58Z","timestamp":1775835058000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2847639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.4901","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}